Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesAppili Therapeutics Inc

Appili Therapeutics Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
None CAD 0.00(0%)
Last update at 2026-11-04T19:03:50.498343Z
Market Cap
2.57M

Momentum Score

…

Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a liquid oral taste-masked reformulation of the antibiotic metronidazole to treat anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a novel topical formulation of paromomycin for the treatment of cutaneous leishmaniasis; and ATI-1701, a live-attenuated vaccine for the treatment of francisella tularensis. The company was incorporated in 2015 and is headquartered in Halifax, Canada.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
0.01
Low
0.04
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Appili Therapeutics Inc is a clinical-stage Canadian biopharmaceutical company developing small-molecule anti-infective therapies targeting viral and bacterial diseases. Long-term growth drivers include advancement of its pipeline through regulatory milestones, potential partner collaborations, and unmet need for effective infectious disease treatments; these factors may benefit future revenue potential and value creation.
Key investment risks include high clinical and regulatory uncertainty, need for additional financing, trial failure or competitive alternatives, and limited current revenues.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
-
Dividend Yield
-
Revenue TTM
0.21M
Revenue Per Share
0.00
Gross Profit TTM
0.21M
Debt / Equity
-0.75
ROE
-938.72%
Net Debt
11.07M
ROCE
-2.74%
Diluted EPS TTM
-0.02

Insight Announcement

View All

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-03-31 2024-03-31 2023-03-31 2022-12-31 2022-03-31
Type yearly yearly yearly yearly yearly
Date 2025-03-31 2024-03-31 2023-03-31 2022-12-31 2022-03-31
Income before tax -2.61M -3.74M -9.21M -9.21M -25.08M
Net income -2.62M -3.78M -9.24M -9.24M -25.12M
Selling general administrative 2.85M 3.05M 4.44M 4.60M 4.56M
Selling and marketing expenses - 0.14M 0.19M - 0.71M
Gross profit 0.10M 0.81M 0.33M - 1.39M
Reconciled depreciation 0.01M 0.01M 0.01M 0.01M 0.01M
Ebit 0.35M -8.02M -7.75M - -23.52M
Ebitda 0.36M -8.01M -7.74M -8.10M -23.51M
Depreciation and amortization 0.01M 0.01M 0.01M - 0.01M
Operating income -0.19M -8.02M -7.91M -7.91M -24.68M
Other operating expenses 0.29M 8.85M 8.11M - 24.95M
Interest expense 3.50M 1.63M 1.10M 1.10M 1.55M
Tax provision 0.02M 0.07M 0.04M 0.04M 0.04M
Interest income 3.83M 0.02M 1.43M 1.43M 0.03M
Net interest income -3.50M -1.61M -1.07M -1.07M -1.52M
Income tax expense 0.02M 0.04M 0.04M - 0.04M
Total revenue 0.10M 0.83M 0.33M 0.33M 1.39M
Total operating expenses 0.29M 8.84M 8.11M 8.11M 24.95M
Cost of revenue - 0.01M 0.01M - -
Total other income expense net -2.42M 4.28M -0.36M -0.36M -0.40M
Net income from continuing ops -2.62M -3.78M -9.24M -9.24M -25.12M
Net income applicable to common shares -2.62M - -9.24M -9.24M -25.12M
Breakdown 2025-03-31 2024-03-31 2023-03-31 2022-12-31 2022-03-31
Type yearly yearly yearly yearly yearly
Date 2025-03-31 2024-03-31 2023-03-31 2022-12-31 2022-03-31
Total assets 3.03M 1.49M 3.13M 3.13M 8.28M
Other current assets - 0.19M 0.23M - 0.18M
Total liab 16.43M 12.42M 10.53M 10.53M 11.55M
Total stockholder equity -13.40M -10.92M -7.40M -7.40M -3.27M
Other current liab - 0.08M 0.23M - 0.12M
Common stock 42.32M 42.32M 42.32M 42.32M 39.65M
Capital stock 42.32M 42.32M 42.32M 42.32M 39.65M
Retained earnings -70.54M -69.09M -65.31M -56.13M -56.07M
Other assets - 0.00M - - -
Cash 1.23M 0.09M 2.47M 2.47M 6.66M
Total current liabilities 15.69M 11.54M 2.98M 2.98M 6.67M
Current deferred revenue - 0.05M -0.19M - -
Net debt 11.07M 8.09M 5.20M 5.20M -1.69M
Short term debt 0.00M 7.31M 0.11M 0.00M 0.10M
Short long term debt 11.56M 7.31M 0.11M 0.11M 0.10M
Short long term debt total - 8.18M 7.67M - 4.98M
Other stockholder equity - 12.87M 6.41M - 13.15M
Property plant equipment 0.02M - 0.01M 0.01M 0.04M
Total current assets 3.01M 1.46M 3.12M 3.12M 8.24M
Net tangible assets - - - - -3.27M
Short term investments - - - - 0.00M
Net receivables 1.50M 1.17M 0.42M 0.00M 1.39M
Long term debt 0.74M 0.88M 7.55M 7.55M 4.88M
Accounts payable 4.11M 4.11M 2.82M 2.82M 6.46M
Accumulated other comprehensive income - 2.98M 9.18M - 8.13M
Non currrent assets other - -0.00M -0.01M - -0.04M
Non current assets total 0.02M 0.03M 0.01M 0.01M 0.04M
Long term debt total 0.74M - 7.55M 7.55M 4.88M
Breakdown 2025-03-31 2024-03-31 2023-03-31 2022-12-31 2022-03-31
Type yearly yearly yearly yearly yearly
Date 2025-03-31 2024-03-31 2023-03-31 2022-12-31 2022-03-31
Investments -0.00M -0.03M -0.00M -0.00M 5.06M
Change to liabilities - - - - 1.65M
Total cashflows from investing activities -0.00M - -0.00M -0.00M 5.06M
Net borrowings 0.26M - - - 3.83M
Total cash from financing activities 0.19M 0.19M 5.91M 5.91M 9.56M
Change to operating activities - - - - 0.27M
Net income -2.62M -3.78M -9.24M -9.24M -25.12M
Change in cash 1.13M -2.37M -4.20M -4.20M -4.40M
Begin period cash flow 0.09M 2.47M 6.66M 6.66M 11.06M
End period cash flow 1.23M 0.09M 2.47M 2.47M 6.66M
Total cash from operating activities 0.87M -2.54M -10.10M -10.10M -19.08M
Issuance of capital stock - 0.00M 3.21M 3.21M 5.34M
Depreciation 0.01M 0.01M 0.01M 0.01M 0.01M
Other cashflows from investing activities 0.00M - 0.00M 0.00M 5.06M
Dividends paid 0.00M 0.00M 0.00M 0.00M 0.00M
Change to inventory - - 4.16M - -1.92M
Change to account receivables -0.50M -0.75M 0.35M 0.35M 0.57M
Sale purchase of stock - - 4.50M 4.50M 7.04M
Other cashflows from financing activities -0.06M -0.01M 2.78M -1.01M 8.39M
Change to netincome - - - - 3.54M
Capital expenditures 0.00M 0.03M 0.00M 0.00M 0.00M
Change in working capital -0.23M 0.66M -3.24M -3.24M 2.49M
Stock based compensation 0.12M 0.19M 0.88M 0.88M 2.04M
Other non cash items 3.59M 1.35M 1.10M 1.10M 1.55M
Free cash flow 0.87M -2.57M -10.10M -10.10M -19.08M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(CAD)
Price
(CAD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
EPRX
Eupraxia Pharmaceuticals Inc		 0.03
0.31%		 9.68 - - - 8.45 - -3.88
FRX
Fennec Pharmaceuticals Inc		 0.20
1.35%		 14.99 - 21.01 6.95 6.35 4.25 20.27
MSCL
Satellos Bioscience Inc.		 -
-%		 9.00 - - - 5.85 - 6.47
HBP
Helix BioPharma Corp.		 -0.10
9.80%		 0.92 - 3.87 4263.36 9.74 4422.35 -6.36

Profile*

Appili Therapeutics Inc

Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a liquid oral taste-masked reformulation of the antibiotic metronidazole to treat anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a novel topical formulation of paromomycin for the treatment of cutaneous leishmaniasis; and ATI-1701, a live-attenuated vaccine for the treatment of francisella tularensis. The company was incorporated in 2015 and is headquartered in Halifax, Canada.

1344 Summer Street, Halifax, NS, Canada, B3H 0A8

902 442 4655

https://appilitherapeutics.com

7

Name Title Year Born
Dr. Donald D. Cilla Jr., M.B.A., Pharm.D., Pharmd CEO, Pres & Director NA
Mr. Kenneth G. Howling Acting Chief Financial Officer NA
Dr. Yoav Golan M.S., M.D., MS Chief Medical Officer 1962
Dr. Donald D. Cilla Jr., M.B.A., Pharmd CEO, President & Director NA
Mr. Kenneth G. Howling Chief Financial Officer NA
Dr. Gary S. Nabors Ph.D. Chief Development Officer NA
Dr. Carl Gelhaus Ph.D. Director of Non-Clinical Research NA
Mr. Arthur Baran Director of New Product Development NA
Jenna McNeil Corporate Affairs & Communications Manager NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

PRL
CAD 30.34
+14.45%
OMG
CAD 1.70
+13.76%
ARTG
CAD 39.54
+12.59%
DSV
CAD 10.83
+12.58%
TLRY
CAD 4.17
+12.10%
DRUG
CAD 25.95
-30.02%
HUT
CAD 69.16
-22.20%
UCU
CAD 2.04
-16.39%
PHX
CAD 10.70
-15.62%
VET
CAD 15.04
-13.31%

Equity Sectors*

  • Basic Materials

    +4.80%

  • Communication Services

    +2.78%

  • Consumer Cyclical

    +2.82%

  • Consumer Defensive

    +0.74%

  • Energy

    -4.92%

  • Financial Services

    +2.47%

  • Healthcare

    -0.30%

  • Industrials

    -0.38%

  • Real Estate

    +1.75%

  • Technology

    +0.82%

  • Utilities

    +1.29%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…